Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG). The Company’s drug candidate is CaPre, an OM3 phospholipid, which is being developed for the treatment of severe hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides in the bloodstream (over 500 mg/dL) (severe hypertriglyceridemia or severe HTG).
Market Cap:191.7M; Shares Outstanding:88M; Short Interest: 2.76%; Q4 2019(12/31/19): Cash 26.23M. Loss 2.82M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 28，no change
Shares hold: 3523k shares. no change
shares% hold: 4.15%，no change